Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNF alpha therapy and discontinuation of glucocorticoids
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10190172" target="_blank" >RIV/00216208:11110/13:10190172 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00023728:_____/13:#0004097
Výsledek na webu
<a href="http://dx.doi.org/10.1007/s00296-013-2678-3" target="_blank" >http://dx.doi.org/10.1007/s00296-013-2678-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00296-013-2678-3" target="_blank" >10.1007/s00296-013-2678-3</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNF alpha therapy and discontinuation of glucocorticoids
Popis výsledku v původním jazyce
Juvenile idiopathic arthritis (JIA) is an inflammatory disease associated with bone loss and low bone mineral density (BMD). The treatment involves disease-modifying antirheumatic drugs, glucocorticoids (GCs) and biological agents. The aim of this studywas to evaluate effects of 12-month therapy with the anti-tumor necrosis factor alpha (anti-TNF alpha) preparations on bone mineral density (BMD) and biochemical turnover markers (BTM) in adult patients with JIA who were previously either treated or nottreated with glucocorticoids (GC) and to assess effects of the discontinuation of GCs on their bone status. Nineteen adult patients (12 women, 7 men) aged 18-33 years with active JIA were prospectively enrolled to receive the anti-TNF alpha therapy (infliximab, etanercept or adalimumab). BMD and BTMs were determined at baseline and 1-year follow-up. The anti-TNF alpha therapy resulted in a significant reduction in disease activity score 28 (DAS28) and C-reactive protein (CRP) and a signi
Název v anglickém jazyce
Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNF alpha therapy and discontinuation of glucocorticoids
Popis výsledku anglicky
Juvenile idiopathic arthritis (JIA) is an inflammatory disease associated with bone loss and low bone mineral density (BMD). The treatment involves disease-modifying antirheumatic drugs, glucocorticoids (GCs) and biological agents. The aim of this studywas to evaluate effects of 12-month therapy with the anti-tumor necrosis factor alpha (anti-TNF alpha) preparations on bone mineral density (BMD) and biochemical turnover markers (BTM) in adult patients with JIA who were previously either treated or nottreated with glucocorticoids (GC) and to assess effects of the discontinuation of GCs on their bone status. Nineteen adult patients (12 women, 7 men) aged 18-33 years with active JIA were prospectively enrolled to receive the anti-TNF alpha therapy (infliximab, etanercept or adalimumab). BMD and BTMs were determined at baseline and 1-year follow-up. The anti-TNF alpha therapy resulted in a significant reduction in disease activity score 28 (DAS28) and C-reactive protein (CRP) and a signi
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FE - Ostatní obory vnitřního lékařství
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Rheumatology International
ISSN
0172-8172
e-ISSN
—
Svazek periodika
33
Číslo periodika v rámci svazku
8
Stát vydavatele periodika
DE - Spolková republika Německo
Počet stran výsledku
7
Strana od-do
2001-2007
Kód UT WoS článku
000322120400012
EID výsledku v databázi Scopus
—